Form 4: Baker Bros. Advisors Report Beneficial Ownership Change in IGM Biosciences

Baker Bros. Advisors LP reports changes in beneficial ownership of IGM Biosciences stock due to the issuance of restricted stock units (RSUs) in lieu of director retainer fees.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in their beneficial ownership of IGM Biosciences, Inc. (IGMS) stock.
• The filing reports the acquisition of 1,994 restricted stock units (RSUs) by Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, in lieu of director retainer fees of $11,500.
• These RSUs are fully vested and were issued under IGM Biosciences' Outside Director Compensation Policy.
• The reported transaction does not involve a cash outlay, as the RSUs were received in place of director fees.
• After the transaction, Baker Bros. entities and related individuals maintain significant indirect ownership positions in IGM Biosciences common stock.
• The filing clarifies the relationships between Baker Bros. Advisors LP, its general partners, and the various funds they advise, emphasizing the investment and voting power held by the Adviser.
• The filing also includes disclaimers of beneficial ownership by Julian C. Baker, Felix J. Baker, the Adviser GP, and the Adviser, except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of insider transactions related to director compensation. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The receipt of RSUs in lieu of cash compensation can be seen as a positive signal, indicating confidence in the company's future performance.
• Baker Bros.' continued significant ownership stake suggests ongoing commitment to IGM Biosciences.

Future Outlook

The document does not contain specific forward-looking statements regarding IGM Biosciences' future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the ownership positions and transactions of company insiders. This filing reflects standard compensation practices for board members in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Director compensation practices vary across the biotech industry, but the use of stock-based compensation, such as RSUs, is common.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and RSUs as part of their director compensation packages.
• The amount of RSUs granted in lieu of cash fees appears to be within the typical range for biotech companies of similar size and stage of development as IGM Biosciences.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• Shareholders may view the acceptance of RSUs in lieu of cash as a positive sign of director alignment with company performance.

Key Dates